T1	intervention 17 38	biosimilar filgrastim
T2	control 43 90	original granulocyte colony-stimulating factors
T3	eligibility 371 482	breast cancer patients receiving docetaxel/doxorubicin/cyclophosphamide (TAC) as adjuvant/neoadjuvant treatment
T5	outcome-Measure 720 732	FN incidence
T7	total-participants 952 954	98
T8	outcome 1106 1118	FN incidence
T9	cv-bin-percent 1147 1151	3.7%
T10	iv-bin-percent 1165 1169	3.3%
T11	outcome 1248 1289	moderate and severe neutropenia incidence
T12	cv-bin-percent 1291 1294	4.7
T13	iv-bin-percent 1299 1303	6.3%
T14	outcome 1318 1354	neutropenia-related hospitalizations
T15	cv-bin-percent 1356 1359	3.3
T16	iv-bin-percent 1364 1368	3.6%
T17	outcome 1438 1450	FN incidence
T19	iv-cont-mean 1598 1601	4.9
T20	cv-cont-mean 1606 1619	5.7 μg/kg/day
T21	iv-cont-mean 1621 1622	5
T22	cv-cont-mean 1627 1633	7 days
T4	outcome 1535 1554	dosage and duration
